Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Vistagen Therapeutics Inc (VTGN)

56 + Investors. Track Smart Money conviction in VTGN. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
56%

Smart Money Signals — VTGN

Based on 56 hedge funds · latest filing: 2026 Q1 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
🏔️

At the ownership peak (97% of max)

97% of all-time peak
56 hedge funds hold VTGN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +14% more funds vs a year ago

fund count last 6Q
+7 new funds entered over the past year (+14% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 56% buying

33 buying26 selling
Last quarter: 33 funds bought or added vs 26 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~15 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 6 → 14 → 15 → 15. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

66% of holders stayed for 2+ years

■ 66% conviction (2yr+) ■ 16% medium ■ 18% new
37 out of 56 hedge funds have held VTGN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -1%, value -18%

Value
-18%
Shares
0%
Last quarter: funds added -1% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

3 → 6 → 14 → 15 → 15 new funds/Q
New funds entering each quarter: 6 → 14 → 15 → 15. A growing number of institutions are discovering VTGN each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 73% veterans vs 18% newcomers

■ 73% veterans ■ 8% 1-2yr ■ 18% new
Entry-cohort mix of 60 holders: 44 (73%) are 2+ year veterans, 5 entered 1–2 years ago, and 11 (18%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 12% AUM from top-100

12% from top-100 AUM funds
14 of 55 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.4
out of 10
Low Exit Risk
Exit risk score 3.4/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — VTGN

In 2026 Q1, 33 hedge funds were net buyers of VTGN (15 opened a new position, 18 added to an existing one), while 26 reduced or exited (11 trimmed, 15 sold completely) — a 56% buyer ratio, indicating a slight buying edge. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 56.

Hedge Fund Ownership: VTGN

How many hedge funds hold VTGN — quarterly history vs. share price
Quarterly hedge fund ownership of VTGN vs. share price

Market Analysis: VTGN

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: VTGN

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Vistagen Therapeutics Inc (VTGN) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much VTGN has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
VTGN
+21.4%
XLV
+3.1%

VTGN outperformed XLV by +18.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
VTGN
+11.9%
XLV
+4.2%

Since the filing became public, VTGN outperformed XLV by +7.7% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

6 top-rated funds 0 high-conviction
Consensus
3.7
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: VTGN
56 + Investors

Track Smart Money conviction in VTGN. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 56 56 -
13F Shares 15M 16M -0.74%
Total Value $8M $10M -18.47%
New Positions 15 15 -
Increased Positions 14 19 -5
Closed Positions 15 17 -2
Reduced Positions 12 15 -3
Total Calls 4 6 -33.33%
Total Puts 1 4 -75.0%
PUT/CALL Ratio 0.25 0.67 Bullish

Statistics: VTGN

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

56 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VTGN. Verified SEC 13F-HR filings.

QUARTER:
Top 25 VTGN holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Luminus Management LLC 0.14% 396,053 $226K
2 Verdad Advisers, LP 0.12% 184,938 $106K
3 TCG Crossover Management, LLC 0.04% 2,676,580 $1.5M
4 Orbimed Advisors LLC 0.03% 3,060,000 $1.7M
5 AdvisorShares Investments LLC 0.03% 277,110 $158K
6 ADAR1 Capital Management, LLC 0.03% 751,141 $429K
7 Ikarian Capital, LLC 0.02% 519,077 $297K
8 Diadema Partners LP 0.01% 105,428 $60K
9 Shay Capital LLC 0.01% 144,452 $83K
10 Persistent Asset Partners Ltd 0.01% 26,612 $15K
11 Truvestments Capital LLC 0.00% 16,992 $10K
12 XTX Topco Ltd 0.00% 152,849 $87K
13 Two Sigma Securities, LLC 0.00% 16,495 $9K
14 Boothbay Fund Management, LLC 0.00% 134,571 $77K
15 Performa Ltd (US), LLC 0.00% 7,500 $4K
16 StoneX Group Inc. 0.00% 15,198 $9K
17 Renaissance Technologies LLC 0.00% 291,300 $166K
18 Two Sigma Investments, LP 0.00% 469,619 $268K
19 Two Sigma Advisers, LP 0.00% 137,732 $91K
20 Tudor Investment Corp Et Al 0.00% 106,172 $61K
21 Schonfeld Strategic Advisors LLC 0.00% 26,589 $15K
22 Millennium Management LLC 0.00% 430,404 $246K
23 Kestra Advisory Services, LLC 0.00% 26,000 $15K
24 Annis Gardner Whiting Capital Advisors, LLC 0.00% 600 —
25 Millennium Management LLC 0.00% 214,000 $122K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Vistagen Therapeutics Inc (VTGN)

What does the Smart Money Trend signal show for VTGN?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for VTGN?

Slight buying edge — 56% buying: Last quarter: 33 funds bought or added vs 26 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for VTGN holders?

Smaller funds dominant — 12% AUM from top-100: 14 of 55 holders rank in the top 100 by AUM, but together hold only 12% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held VTGN?

66% of holders stayed for 2+ years: 37 out of 56 hedge funds have held VTGN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Vistagen Therapeutics Inc (VTGN) following the 2026 Q1 hedge fund 13F filings?

As of today, VTGN has moved +11.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +4.2% for the XLV sector ETF — an outperformance of +7.7%. Since the quarter end (March 31, 2026), VTGN has gained +21.4% vs +3.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →